Atossa logo
Aug 26, 2020
Atossa Therapeutics to Present at the LD Micro 500 Virtual Conference on September 4, 2020

Aug 17, 2020
Atossa Therapeutics Announces Enrollment and Dosing Completed in First Group of Healthy Participants in Clinical Study of AT-301 Nasal Spray Being Developed for Treatment of COVID-19

Aug 13, 2020
Atossa Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update

Aug 03, 2020
Atossa Therapeutics Receives Approval to Open Clinical Study of AT-301 Nasal Spray Being Developed to Treat COVID-19

Jul 30, 2020
Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen

Jul 27, 2020
Registration Is Now Open for Atossa Therapeutics' Tribe Public Webinar Presentation and Q&A Event on July 30, 2020

Jul 16, 2020
Atossa Therapeutics Contracts for Clinical Study of AT-301 Nasal Spray, Atossa's Second COVID-19 Therapeutic Development Program

Jul 15, 2020
Atossa Therapeutics Announces Successful In Vitro Testing of Nasal Spray Formulation: AT-301 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture

Jul 08, 2020
Atossa Therapeutics Advances Product Development Programs with Multiple Key Hires in Clinical, Regulatory, and Chemistry Manufacturing and Controls

Jun 11, 2020
Atossa Therapeutics Announces Availability of Manuscript on Results from In vitro Testing of COVID-19 Drug, AT-H201

 1   2   3   4   5     6    7   8   9   10   11